Objective: To analyze the clinical efficacy of Qianggan Capsules combined with tenofovir propofol in the treatment of Chronic Hepatitis B (CHB). Method: Sixty patients with CHB admitted to our hospital from January 2022 to December 2024 were selected as the research subjects. The patients were divided into the control group and the observation group by random number table method, with 30 cases in each group. The control group was treated with tenofovir propofol. The observation group was treated with Qianggan Capsules combined with tenofovir propofol. The negative conversion rate of Hepatitis B virus DNA (HBV-DNA), the normalization rate of Alanine aminotransferase (ALT), and liver fibrosis indicators [serum Hyaluronic acid (HA), Laminin (LN), Procollagr type Ⅲ (PCⅢ)] and liver function indicators [Total bilirubin in serum (TBIL), Aspartate aminotransferase (AST), and ALT levels] of the two groups were analyzed and compared. Result: The HBV-DNA negative conversion rate and ALT normalization rate in the observation group after treatment were significantly higher than those in the control group (P < 0.05). After treatment, the levels of serum HA, LN and PCⅢ in both groups were significantly lower than those before treatment, and the levels of serum HA, LN and PCⅢ in the observation group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of serum TBIL, AST and ALT in both groups were significantly lower than those before treatment, and the levels of serum TBIL, AST and ALT in the observation group were significantly lower than those in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups during the treatment period (P > 0.05). Conclusion: Qianggan Capsules combined with tenofovir propofol in the treatment of CHB can increase the negative conversion rate of HBV-DNA and the normalization rate of ALT, inhibit liver fibrosis, improve liver function of patients, and has relatively high safety.